Huaxia Eye Hospital Group (301267) Fair Value & Analysis
Healthcare · CN · Market cap 13.6B CNY
Fair value as of: Jul 9, 2026
From 24 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥12.68 to ¥16.94 (+33.6%) since Jun 24, 2026. Share price +9.6% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥12.71 (bear) to ¥21.18 (bull), base ¥16.94. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 72/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
45‑month range ¥14.59 – ¥61.46 · fair‑value band ¥12.71 – ¥21.18 · the ¥16.15 price screens below the ¥16.94 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Huaxia Eye Hospital Group (301267) currently trades at ¥16.15, while our model-based Fair Value estimate is ¥16.94, implying the stock looks roughly 4.9% fairly valued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Huaxia Eye Hospital Group generated revenue of 4.2B CNY at a net margin of 11.0%. Revenue grew 5.2% year over year. It earns a return on equity of 7.7%. The stock trades on a trailing P/E of 29.4. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥12.71 (bear case) to ¥21.18 (bull case); at ¥16.15, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 5%, 301267 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (¥14.89) versus Earnings-Based (¥3.23). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Huaxia Eye Hospital Group Co.,Ltd. operates an ophthalmic medical chain in China and internationally. The company provides general ophthalmology diagnosis, treatment, and other ophthalmic medical services for patients with eye disease and myopia; prevention and intervention work to the public.
Full company description
Huaxia Eye Hospital Group Co.,Ltd. operates an ophthalmic medical chain in China and internationally. The company provides general ophthalmology diagnosis, treatment, and other ophthalmic medical services for patients with eye disease and myopia; prevention and intervention work to the public. It offers services in the areas of cataract, refractive errors, fundus, strabismus and amblyopia, pediatric ophthalmology, ocular surface, glaucoma, orbital and ocular tumors, optometry, and ocular trauma, as well as engages in community services. The company was founded in 1997 and is based in Xiamen, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Huaxia Eye Hospital Group reported revenue of ¥4.1B in FY2025 versus ¥3.1B in FY2021, a compound +7.8%/yr. Reported net income was ¥441M in FY2025, compounding −0.8%/yr from FY2021.
Watch 301267: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Huaxia Eye Hospital Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Huaxia Eye Hospital Group (301267) overvalued or undervalued?
What is the fair value of 301267?
What is the quality score of 301267?
What is the revenue of Huaxia Eye Hospital Group (301267)?
What is the net profit margin of 301267?
Does Huaxia Eye Hospital Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Huaxia Eye Hospital Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.